menu
    • menu
    [{"orgOrder":0,"company":"Innovate Biopharmaceuticals","sponsor":"Storm Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Innovate Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Innovate Biopharmaceuticals \/ Innovate Biopharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"Innovate Biopharmaceuticals \/ Innovate Biopharmaceuticals"},{"orgOrder":0,"company":"Innovate Biopharmaceuticals","sponsor":"UK Government","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Funding","leadProduct":"Mov18 IgE","moa":"Folate-alpha receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Innovate Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovate Biopharmaceuticals \/ UK Government","highestDevelopmentStatusID":"6","companyTruncated":"Innovate Biopharmaceuticals \/ UK Government"},{"orgOrder":0,"company":"Innovate Biopharmaceuticals","sponsor":"Theolytics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2024","type":"Funding","leadProduct":"THEO-260","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innovate Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovate Biopharmaceuticals \/ Innovate Biopharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Innovate Biopharmaceuticals \/ Innovate Biopharmaceuticals"},{"orgOrder":0,"company":"Innovate Biopharmaceuticals","sponsor":"Epitopea","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Innovate Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Innovate Biopharmaceuticals \/ Innovate Biopharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Innovate Biopharmaceuticals \/ Innovate Biopharmaceuticals"},{"orgOrder":0,"company":"Innovate Biopharmaceuticals","sponsor":"Senisca","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Innovate Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Innovate Biopharmaceuticals \/ Innovate Biopharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Innovate Biopharmaceuticals \/ Innovate Biopharmaceuticals"},{"orgOrder":0,"company":"Innovate Biopharmaceuticals","sponsor":"LIfT Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Innovate Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Innovate Biopharmaceuticals \/ Innovate Biopharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Innovate Biopharmaceuticals \/ Innovate Biopharmaceuticals"},{"orgOrder":0,"company":"Innovate Biopharmaceuticals","sponsor":"Sixfold Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Innovate Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Innovate Biopharmaceuticals \/ Innovate Biopharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Innovate Biopharmaceuticals \/ Innovate Biopharmaceuticals"},{"orgOrder":0,"company":"Innovate Biopharmaceuticals","sponsor":"LabGenius","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Innovate Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Innovate Biopharmaceuticals \/ Innovate Biopharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"Innovate Biopharmaceuticals \/ Innovate Biopharmaceuticals"},{"orgOrder":0,"company":"Innovate Biopharmaceuticals","sponsor":"RDD Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Merger","leadProduct":"Larazotide Acetate","moa":"Neuronal acetylcholine receptor; alpha3\/beta4","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Innovate Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovate Biopharmaceuticals \/ RDD Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Innovate Biopharmaceuticals \/ RDD Pharma"},{"orgOrder":0,"company":"Innovate Biopharmaceuticals","sponsor":"Epsilogen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Funding","leadProduct":"EPS 201","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Innovate Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovate Biopharmaceuticals \/ Innovate Biopharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Innovate Biopharmaceuticals \/ Innovate Biopharmaceuticals"},{"orgOrder":0,"company":"Innovate Biopharmaceuticals","sponsor":"Mestag Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2024","type":"Funding","leadProduct":"MST-0300","moa":"FAP","graph1":"Oncology","graph2":"Preclinical","graph3":"Innovate Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovate Biopharmaceuticals \/ Innovate Biopharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Innovate Biopharmaceuticals \/ Innovate Biopharmaceuticals"},{"orgOrder":0,"company":"Innovate Biopharmaceuticals","sponsor":"ThirtyFiveBio","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Innovate Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovate Biopharmaceuticals \/ Innovate Biopharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Innovate Biopharmaceuticals \/ Innovate Biopharmaceuticals"},{"orgOrder":0,"company":"Innovate Biopharmaceuticals","sponsor":"Rinri Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"Innovate Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovate Biopharmaceuticals \/ Innovate Biopharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Innovate Biopharmaceuticals \/ Innovate Biopharmaceuticals"},{"orgOrder":0,"company":"Innovate Biopharmaceuticals","sponsor":"NRG Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Innovate Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Innovate Biopharmaceuticals \/ Innovate Biopharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Innovate Biopharmaceuticals \/ Innovate Biopharmaceuticals"},{"orgOrder":0,"company":"Innovate Biopharmaceuticals","sponsor":"Scancell","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Innovate Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Innovate Biopharmaceuticals \/ Innovate Biopharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Innovate Biopharmaceuticals \/ Innovate Biopharmaceuticals"},{"orgOrder":0,"company":"Innovate Biopharmaceuticals","sponsor":"Pathios Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Innovate Biopharmaceuticals","amount2":0.47999999999999998,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.47999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Innovate Biopharmaceuticals \/ Innovate Biopharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Innovate Biopharmaceuticals \/ Innovate Biopharmaceuticals"},{"orgOrder":0,"company":"Innovate Biopharmaceuticals","sponsor":"VaxEquity","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"saRNA Influenza Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Innovate Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovate Biopharmaceuticals \/ Innovate Biopharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Innovate Biopharmaceuticals \/ Innovate Biopharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by Innovate Biopharmaceuticals

    Menu

    Innovate Biopharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Innovate Biopharmaceuticals

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed

                            Innovate Biopharmaceuticals

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Epitopea

                            Deal Size : $0.6 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Epitopea Awarded Grant from Innovate UK’s Cancer Therapeutics Programme

                            Details : The net proceeds from the funding will be used to advance the development of company's Cryptigen immunotherapeutics, discovered by Epitopea’s CryptoMap platform, for cancer.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            December 09, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Epitopea

                            Deal Size : $0.6 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Innovate Biopharmaceuticals

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed

                            Innovate Biopharmaceuticals

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MST-0300

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Mestag Therapeutics

                            Deal Size : $1.9 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Mestag Gets £1.5M from Innovate UK For Cancer Therapy Development

                            Details : The proceeds will be used to accelerate the development of company's MST-0300, a first-in-class bispecific antibody designed to induce TLS in solid tumors.

                            Product Name : Undisclosed

                            Product Type : Other Large Molecule

                            Upfront Cash : Undisclosed

                            August 29, 2024

                            Lead Product(s) : MST-0300

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Mestag Therapeutics

                            Deal Size : $1.9 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Innovate Biopharmaceuticals

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed

                            Innovate Biopharmaceuticals

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : LIfT Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            LIfT BioSciences Gets UK Grant For IMAN Cell Therapy Development

                            Details : The grant will enable LIfT to show how its immunomodulatory alpha neutrophils recruit immune cells in vivo to attack tumours using a new type of translational humanised mouse model.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            May 16, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : LIfT Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Innovate Biopharmaceuticals

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed

                            Innovate Biopharmaceuticals

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : THEO-260

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Theolytics

                            Deal Size : $2.2 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Theolytics Awarded Significant £2M Transforming Cancer Therapeutics Grant from Innovate UK

                            Details : The proceeds will be used to support the clinical development of its lead candidate THEO-260, a next-generation oncolytic adenovirus for the treatment of ovarian cancer.

                            Product Name : Undisclosed

                            Product Type : Microorganism

                            Upfront Cash : Undisclosed

                            February 09, 2024

                            Lead Product(s) : THEO-260

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Theolytics

                            Deal Size : $2.2 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Innovate Biopharmaceuticals

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed

                            Innovate Biopharmaceuticals

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Gastroenterology

                            Study Phase : Preclinical

                            Recipient : ThirtyFiveBio

                            Deal Size : $0.8 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            ThirtyFiveBio Wins Grant to Advance GPR35 Inhibitor for Ulcerative Colitis

                            Details : The funding will support ThirtyFiveBio in developing first-in-class small molecule inhibitors of G protein-coupled receptor 35 for the treatment of gastrointestinal diseases.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            February 07, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Preclinical

                            Recipient : ThirtyFiveBio

                            Deal Size : $0.8 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Innovate Biopharmaceuticals

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed

                            Innovate Biopharmaceuticals

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : saRNA Influenza Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Recipient : VaxEquity

                            Deal Size : $0.8 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            VaxEquity and CPI Announces Innovate UK Grant to Accelerate Next Generation RNA Vaccines and Therapeutics

                            Details : The funding will advance the manufacturing process for RNA vaccines and therapeutics including, saRNA influenza vaccine based on VaxEquity's next generation self-amplifying RNA (saRNA) platform.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            May 06, 2023

                            Lead Product(s) : saRNA Influenza Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Recipient : VaxEquity

                            Deal Size : $0.8 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Innovate Biopharmaceuticals

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed

                            Innovate Biopharmaceuticals

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Preclinical

                            Recipient : Senisca

                            Deal Size : $0.7 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            SENISCA Awarded Innovate UK Grant to Develop Oligonucleotide Therapeutics for The Treatment of Idiopathic Pulm...

                            Details : The funding will be used towards the development of Oligonucleotide-based Thearpies for the treatment of idiopathic pulmonary fibrosis (IPF), using SENISCA’s proprietary technology, harnessing RNA biology to rejuvenate aged senescent cells.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            April 20, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Preclinical

                            Recipient : Senisca

                            Deal Size : $0.7 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Innovate Biopharmaceuticals

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed

                            Innovate Biopharmaceuticals

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Recipient : LabGenius

                            Deal Size : $1.2 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            LabGenius Wins Government Innovation Grant to Support the Development of ML-driven Cancer Therapies

                            Details : LabGenius is pioneering the development of an ML-driven protein engineering platform. To date, EVA has co-optimised mono- and multi-specific single domain antibodies for biochemical and biofunctional properties, including stability, potency and selective...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            November 30, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Recipient : LabGenius

                            Deal Size : $1.2 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Innovate Biopharmaceuticals

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed

                            Innovate Biopharmaceuticals

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Recipient : NRG Therapeutics

                            Deal Size : $3.9 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            NRG Therapeutics Announces £2.68M Innovate UK Award to Develop New Medicines to Treat Parkinson's and Motor N...

                            Details : The funding will support the NRG pipeline of brain-penetrant small molecule inhibitors of the mitochondrial permeability transition pore (mPTP) with potential as first-in-class treatments for Parkinson's disease (PD) and motor neuron disease (MND).

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            May 30, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Recipient : NRG Therapeutics

                            Deal Size : $3.9 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Innovate Biopharmaceuticals

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed

                            Innovate Biopharmaceuticals

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Discovery Platform

                            Recipient : Storm Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            STORM Therapeutics Awarded Innovate UK Grant to Discover and Develop a Novel Coronavirus Therapy Targeting an ...

                            Details : The Innovate UK grant will allow STORM to develop a drug acting on a key coronavirus protein that is not targeted by current treatments. Generation of such a drug will provide a valuable option for treating Covid-19 and other coronavirus diseases.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            March 05, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Discovery Platform

                            Recipient : Storm Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth